ABCL635 is an investigational first-in-class anti-NK3R antibody for non-hormonal treatment of moderate-to-severe menopausal vasomotor symptoms.
ABCL635 specifically targets NK3R, a clinically validated complex membrane protein on KNDy neurons in the infundibular nucleus of the hypothalamus that helps regulate body temperature. It is the first AbCellera-led program generated using the company's GPCR and ion channel technologies and is in a Phase 1/2 trial of subcutaneous doses evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and vasomotor symptom frequency and severity.
The intended profile combines efficacy comparable to small molecules with differentiated safety without liver-enzyme monitoring, delivered as a once-monthly subcutaneous self-injection. The program is an internal AbCellera pipeline candidate, and positive top-line Phase 2 results were reported in August 2026 after a single 600 mg dose.
Sebela Pharmaceuticals
Brisdelle
sebelapharma.com
Bayer
Lynkuet
bayer.com
Astellas Pharma
Veozah
astellas.com
| Attribute | Abcl635 | Brisdelle | Lynkuet | Veozah | |
|---|---|---|---|---|---|
| Provider |  | | | Astellas Pharmaastellas.comPublic | |
| Founded | 2012 | — | 1863 | 2005 | |
| Sells To | Enterprise, Government | — | Consumers, Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | — | Recurring, Software, Transactional | Recurring, Software | |
| Ownership | Public | — | Public | Public |
Provider
Founded 2012
Sells To Enterprise, Government
Pricing Model Recurring, Software
Ownership Public
Provider
Founded —
Sells To —
Pricing Model —
Ownership —
Provider
Founded 1863
Sells To Consumers, Enterprise
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider Astellas Pharmaastellas.comPublic
Founded 2005
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
